Genocea Biosciences, Inc. (GNCAQ)
- Previous Close
0.0000 - Open
0.0000 - Bid --
- Ask --
- Day's Range
0.0000 - 0.0000 - 52 Week Range
0.0000 - 0.0031 - Volume
72 - Avg. Volume
0 - Market Cap (intraday)
58 - Beta (5Y Monthly) 21.63
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts. The plan was later approved as Chapter 11 liquidation on May 11, 2023.
www.genocea.comRelated News
Performance Overview: GNCAQ
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GNCAQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GNCAQ
Valuation Measures
Market Cap
5.88k
Enterprise Value
-4.65M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.00
Price/Book (mrq)
0.00
Enterprise Value/Revenue
-2.43
Enterprise Value/EBITDA
0.13
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-57.59%
Return on Equity (ttm)
-525.78%
Revenue (ttm)
1.91M
Net Income Avi to Common (ttm)
-37.19M
Diluted EPS (ttm)
-0.5200
Balance Sheet and Cash Flow
Total Cash (mrq)
20.14M
Total Debt/Equity (mrq)
125.03%
Levered Free Cash Flow (ttm)
-31.45M